• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Validation of the Bulgarian versions of the EORTC QLQ-C30 and FACT-G: reliability, construct validity, and agreement in cancer survivors.

作者信息

Peykov Gospodin, Bozov Hristo, Uchikov Angel, Uchikov Petar, Gelov Georgi, Stambolova Desislava, Kashilska Yanna, Bojhkova Maria, Dzhafer Nigyar, Panayotov Kiril, Papathanasiou Jannis

机构信息

Department of Surgery, University Hospital "Sveta Marina", Pleven, Bulgaria.

State University of Burgas Prof. Dr. Asen Zlatarov, Burgas, Bulgaria.

出版信息

Eur J Transl Myol. 2025 Sep 3. doi: 10.4081/ejtm.2025.14121.

DOI:10.4081/ejtm.2025.14121
PMID:40905288
Abstract

Health-related quality of life (HRQoL) is a critical outcome measure in oncology research and clinical care. This study aimed to translate, culturally adapt, and psychometrically validate the Bulgarian versions of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G), focusing on Internal Consistency (IC), Test-Retest Reliability (TRR), and Construct Validity (CV) in Cancer Survivors (CS) diagnosed with breast, lung, or colorectal cancer. A total of 235 Bulgarian CS (mean age 62.3 ± 11.2 years; 118 males, 117 females) were recruited from five tertiary care hospitals in a cross-sectional study design. The EORTC QLQ-C30 and FACT-G were translated and culturally adapted according to the official EORTC and FACIT guidelines. Psychometric evaluation included data quality (floor and ceiling effects, missing responses), IC, TRR, and CV assessed via convergent and Discriminant Validity (DV). A subsample of 78 study participants (33.2%) completed both questionnaires twice over a 14-day interval for TRR assessment. CV was supported by strong item-scale and cross-instrument correlations (r = 0.62-0.81). IC was excellent across all domains (Cronbach's α = 0.88-0.95), and TRR demonstrated high stability (ICC = 0.75-0.89). Bland-Altman analysis showed acceptable agreement, with a mean difference of 23.20 (95% CI: 21.87-24.53) and limits of agreement ranging from +3.77 to +42.63. Minimal Floor Effects (FE) were observed, while Ceiling Effects (CE) were noted in specific domains (e.g., Social Functioning (SF) and Global Health (GH) in the EORTC QLQ-C30; Social Well-Being (SWB) and Emotional Well-Being (EWB) in the FACT-G). The findings support that the Bulgarian versions of the EORTC QLQ-C30 and FACT-G are valid, reliable, and culturally appropriate instruments for evaluating HRQoL in Bulgarian CS. Their use is recommended in both clinical practice and research contexts.

摘要

相似文献

1
Validation of the Bulgarian versions of the EORTC QLQ-C30 and FACT-G: reliability, construct validity, and agreement in cancer survivors.
Eur J Transl Myol. 2025 Sep 3. doi: 10.4081/ejtm.2025.14121.
2
Psychometric Properties of the European Organization for Research and Treatment of Cancer Head and Neck (EORTC QLQ H&N 43) Quality of Life Tool for Use in the Eastern India Population.欧洲癌症研究与治疗组织头颈部(EORTC QLQ H&N 43)生活质量工具在印度东部人群中的心理测量特性。
Indian J Otolaryngol Head Neck Surg. 2025 Jul;77(7):2523-2534. doi: 10.1007/s12070-025-05549-7. Epub 2025 May 16.
3
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.复发或难治性多发性骨髓瘤患者中,贝兰他单抗马福多汀、硼替佐米与地塞米松联合用药对比达雷妥尤单抗、硼替佐米与地塞米松联合用药的患者报告结局(DREAMM-7):一项3期、开放标签、随机对照试验的结果
Lancet Haematol. 2025 Jul 15. doi: 10.1016/S2352-3026(25)00163-2.
4
Health-Related Quality of Life in Chemotherapy Patients Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30): A Single-Institution-Based Study From Lahore, Pakistan.使用欧洲癌症研究与治疗组织生活质量问卷核心30(EORTC QLQ-C30)评估化疗患者的健康相关生活质量:来自巴基斯坦拉合尔的单机构研究。
Cureus. 2025 Jun 23;17(6):e86627. doi: 10.7759/cureus.86627. eCollection 2025 Jun.
5
Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.欧洲癌症研究与治疗组织(EORTC)QLQ-CML24问卷西班牙语版本用于评估慢性髓性白血病患者健康相关生活质量的验证
Ann Hematol. 2025 Jul 22. doi: 10.1007/s00277-025-06516-6.
6
Home-based multidimensional survivorship programmes for breast cancer survivors.针对乳腺癌幸存者的居家多维康复计划。
Cochrane Database Syst Rev. 2017 Aug 24;8(8):CD011152. doi: 10.1002/14651858.CD011152.pub2.
7
Development and validation of crosswalks between the EORTC QLQ-C30 physical, role, social and emotional functioning, fatigue and global health status/quality of life scales and their corresponding PROMIS scales.欧洲癌症研究与治疗组织(EORTC)QLQ - C30身体、角色、社会和情感功能、疲劳及总体健康状况/生活质量量表与相应的患者报告结果测量信息系统(PROMIS)量表之间的转换关系的建立与验证。
J Clin Epidemiol. 2025 May 29;184:111853. doi: 10.1016/j.jclinepi.2025.111853.
8
Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.使用通用和特定疾病健康相关生活质量测量指标进行 NICE 决策制定:系统评价、统计建模和调查。
Health Technol Assess. 2014 Feb;18(9):1-224. doi: 10.3310/hta18090.
9
Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma.癌症特异性效用:欧洲癌症研究与治疗组织生活质量核心问卷-脑肿瘤10项简表(EORTC QLU-C10D)在胶质母细胞瘤患者中的临床验证
Eur J Health Econ. 2024 Nov 20. doi: 10.1007/s10198-024-01729-4.
10
Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change.评估妇科肿瘤学中的健康相关生活质量:问卷及其检测临床重要差异和变化能力的系统评价。
Int J Gynecol Cancer. 2010 May;20(4):664-84. doi: 10.1111/IGC.0b013e3181dad379.